Skip to main
CME

CME Group (CME) Stock Forecast & Price Target

CME Group (CME) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 31%
Hold 31%
Sell 15%
Strong Sell 0%

Bulls say

CME Group has reported a total revenue of $1,649 million for the recent quarter, reflecting a year-over-year increase of approximately 8.1%, with significant contributions from its Market Data segment, which grew by around 14.5% due to new users and pricing strategies. The firm has demonstrated a strong history of free cash flow generation, enabling it to consistently raise its dividend payments for over 14 years, underscoring its financial stability and commitment to returning value to shareholders. Additionally, the company's robust average daily volume (ADV) growth, which has a compound annual growth rate of over 7% from FY16 through FY24, combined with planned revenue enhancements from market data fees, positions CME favorably for continued financial performance and value creation in the future.

Bears say

CME Group faces significant challenges that contribute to a negative financial outlook, primarily characterized by anticipated declines in interest rate futures trading volume due to an ongoing rate-cutting cycle. The company's projected revenue growth of approximately 5.4% year-over-year falls below the consensus estimate of 6.0%, indicating potential underperformance in achieving financial targets. Additionally, regulatory risks, increased competition, and changing industry fundamentals could adversely impact trading volumes and pricing, further compounding concerns regarding the stock's future performance.

CME Group (CME) has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 31% recommend Buy, 31% suggest Holding, 15% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CME Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CME Group (CME) Forecast

Analysts have given CME Group (CME) a Buy based on their latest research and market trends.

According to 13 analysts, CME Group (CME) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $295.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $295.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CME Group (CME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.